Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer (original) (raw)
Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer
Mohammed A. Aleskandarany
Breast Cancer …, 2012
View PDFchevron_right
Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
Dahiana Pulgar
Asian Pacific journal of cancer prevention : APJCP, 2018
View PDFchevron_right
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Sherri Davies
2009
View PDFchevron_right
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
Roman Iglesias
Scientific Reports
View PDFchevron_right
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
Shelley Bull
Modern Pathology, 2014
View PDFchevron_right
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
Mustapha Abubakar
Modern Pathology, 2019
View PDFchevron_right
Ki-67 proliferative index correlation to the immunohistochemistry profile in early female breast cancer: a review of 515 cases
Philip Idaewor
Medical Research Journal
View PDFchevron_right
Intratumoral Heterogeneity of Ki67 Proliferation Index Outperforms Conventional Prognostic Factors in Hormone Receptor-Positive Breast Cancer
Dovile Zilenaite
Research Square (Research Square), 2023
View PDFchevron_right
Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling
Giuseppe Migliaretti
British Journal of Cancer
View PDFchevron_right
Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
natalia valdivieso
Breast Cancer Research, 2011
View PDFchevron_right
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
Mario Airoldi
Breast Cancer Research and Treatment, 2016
View PDFchevron_right
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer
Giuseppe Viale
The Breast, 2014
View PDFchevron_right
A simple and reproducible prognostic index in luminal ER-positive breast cancers
Isabella Castellano, Riccardo Arisio
View PDFchevron_right
KI-67 Index as a Prognostic Factor in Correlation with Other Clinico-Pathological Factors in Breast Cancer – An Institutional Experience
mahin nallasivam
International journal of current research and review, 2021
View PDFchevron_right
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
Greg Harlow
Breast Cancer Research and Treatment, 2019
View PDFchevron_right
Prognostic value of immunohistochemical stratification of invasive duct carcinoma of the breast
Sahar Talaat
The Chinese-German Journal of Clinical Oncology, 2013
View PDFchevron_right
Comparison of diagnostic validity between mitotic activity index and Ki-67 expression as predictor for breast cancer in distant metastasis
Andreasta Ginting
International Journal of Research in Medical Sciences, 2019
View PDFchevron_right
Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression
Mehdi Alimehmeti, Fisnik Kurshumliu
World Journal of Surgical Oncology, 2014
View PDFchevron_right
Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas
Vesna Čapkun
Pathology - Research and Practice, 2013
View PDFchevron_right
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer
Rune Smaaland
Histopathology, 2012
View PDFchevron_right
Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study
Tineke Smilde
Genes, 2018
View PDFchevron_right
Correlation of KI-67 with Prognostic Hormone Receptor Markers in Breast Carcinoma
Joy Augustine
Global journal for research analysis, 2018
View PDFchevron_right
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence
Giuseppe Viale
JAMA oncology, 2015
View PDFchevron_right
Ki-67 Expression in Breast Cancer; Its Association with Grading Systems, Clinical Parameters and Other Prognostic Factors -- A Surrogate Marker?
Rastko Golouh
Deep Blue (University of Michigan), 2003
View PDFchevron_right
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers
Axel Hausen
Breast Cancer Research and Treatment, 2008
View PDFchevron_right
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
Marina Bortul
Tumor Biology, 2020
View PDFchevron_right
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer
Per Malmström
PLoS ONE, 2013
View PDFchevron_right
Old and new markers for breast cancer prognosis: the need for integrated research on quantitative issues
Elia Mario Biganzoli
European Journal of Cancer, 2004
View PDFchevron_right